Pegylated IFN-α2a combined to imatinib mesylate...

Leukemia Research 2011 Vol. 35; Iss. 1

Pegylated IFN-α2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone

Franck E. Nicolini, Sandrine Hayette, Laurence Legros, Philippe Rousselot, Frédéric Maloisel, Michel Tulliez, Agnès Guerci, Aude Charbonnier, Thomas Prébet, Françoise Rigal-Huguet, Kaddour Chabane, Je
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
35
Year:
2011
Language:
english
Pages:
7
DOI:
10.1016/j.leukres.2010.04.010
File:
PDF, 335 KB
english, 2011
Conversion to is in progress
Conversion to is failed